Azilsartan Kamedoxomil (CAS: 863031-24-7)

C30H23N4O8

606.62

Assay:≥99.0%

Azishatan ester potassium salt is a new high blood pressure medicine, developed by takeda, Japan. It is a prodrug of azishatan, which is hydrolyzed to azishatan during gastrointestinal absorption.On February 22, 2011, the FDA approved, sand jotham ester potassium (Azilsartan kamedoxomil potassium) tablets for the treatment of essential hypertension.The Chinese patent no. CN1946717 is for the compound patent of azizatan ester potash in China, which will expire on February 22, 2025.

Temple, sand selective blocking angiotensin Ⅱ and AT1 receptor (temple, sand for AT1 receptor affinity of AT2 receptors of more than 10000 times higher), thereby blocking angiotensin Ⅱ cause vasoconstriction, aldosterone secretion rising blood pressure effect.Its function is not dependent on the angiotensin Ⅱ synthesis way, so to avoid the effect of ACEI on slow excitation peptide level.It can also have a potential protective effect on patients with diabetes by partially activating the peroxisomal proliferator to activate the receptor – (PPAR-). The results of relevant clinical trials show that the clinical effect is better than that of the currently widely used omepratanesters and valsartan.